DAVA Oncology

davaonc.com

Optimize the recruitment and retention of patients in cancer clinical trials through the use of physician-focused approaches. DAVA has a proven track record having completed more than 45 Phase I to III trials and over the past six years with an average accrual enhancement rate of 30-40%.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

BRECKENRIDGE SIGNS NEW-PRODUCT AGREEMENT WITH PTS PHARMA

Breckenridge Pharmaceutical, Inc. | April 23, 2022

news image

Breckenridge Pharmaceutical, Inc. announces today that it has signed a new-product agreement with PTS Pharma, LLC. under which PTS will support a technology transfer to Towa Pharmaceutical Europe, S.L. of a complex "For Suspension" product developed by PTS. The remainder of development and commercialization will be performed at the Towa facility. According to industry sales data, the product and its generics had annual sales of approximately $75 million during the twelve mo...

Read More

Pharmacy Market

HALOZYME ANNOUNCES APPROVAL OF ROCHE'S TECENTRIQ® SUBCUTANEOUS (SC) WITH ENHANZE® IN GREAT BRITAIN

prnewswire | August 29, 2023

news image

Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...

Read More

Research

DISPERSOL TECHNOLOGIES ANNOUNCES COLLABORATION WITH AJAX THERAPEUTICS TO DEVELOP ENHANCED KINETISOL DRUG FORMULATIONS

DisperSol Technologies | December 18, 2021

news image

DisperSol Technologies LLC announced that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies. “Ajax is taking an innovative approach to developing a pipeline of selectively targeted small molecules and we look forward to applying our proprietary KinetiSol technology to help enha...

Read More

Business Insights

PACK4U ACQUIRES LEADING PHARMACY TECHNOLOGY COMPANY CATALYST HEALTHCARE

Pack4U | January 07, 2022

news image

Pack4U, a connected health services company, acquires long-time technology partner Catalyst Healthcare whose patented AdhereNet® platform links pharmacists, patients, and care teams to effectively manage drug complexity and improve medication adherence. "We are dedicated to improving patient outcomes at scale. Bringing this domain knowledge in-house is vital for Pack4U. Catalyst's CEO Shane Bishop is a pharmacy thought leader and we are excited a...

Read More
news image

Business Insights

BRECKENRIDGE SIGNS NEW-PRODUCT AGREEMENT WITH PTS PHARMA

Breckenridge Pharmaceutical, Inc. | April 23, 2022

Breckenridge Pharmaceutical, Inc. announces today that it has signed a new-product agreement with PTS Pharma, LLC. under which PTS will support a technology transfer to Towa Pharmaceutical Europe, S.L. of a complex "For Suspension" product developed by PTS. The remainder of development and commercialization will be performed at the Towa facility. According to industry sales data, the product and its generics had annual sales of approximately $75 million during the twelve mo...

Read More
news image

Pharmacy Market

HALOZYME ANNOUNCES APPROVAL OF ROCHE'S TECENTRIQ® SUBCUTANEOUS (SC) WITH ENHANZE® IN GREAT BRITAIN

prnewswire | August 29, 2023

Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenou...

Read More
news image

Research

DISPERSOL TECHNOLOGIES ANNOUNCES COLLABORATION WITH AJAX THERAPEUTICS TO DEVELOP ENHANCED KINETISOL DRUG FORMULATIONS

DisperSol Technologies | December 18, 2021

DisperSol Technologies LLC announced that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies. “Ajax is taking an innovative approach to developing a pipeline of selectively targeted small molecules and we look forward to applying our proprietary KinetiSol technology to help enha...

Read More
news image

Business Insights

PACK4U ACQUIRES LEADING PHARMACY TECHNOLOGY COMPANY CATALYST HEALTHCARE

Pack4U | January 07, 2022

Pack4U, a connected health services company, acquires long-time technology partner Catalyst Healthcare whose patented AdhereNet® platform links pharmacists, patients, and care teams to effectively manage drug complexity and improve medication adherence. "We are dedicated to improving patient outcomes at scale. Bringing this domain knowledge in-house is vital for Pack4U. Catalyst's CEO Shane Bishop is a pharmacy thought leader and we are excited a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us